Obesity and Outcomes in Adoptive Cellular Therapy in Solid Tumors

Menée sur 95 patients atteints d'une tumeur solide de stade avancé (âge médian : 60,9 ans ; durée médiane de suivi : 39,9 mois), cette étude évalue, en fonction de l'indice de masse corporelle, l'efficacité et la sécurité de thérapies cellulaires adoptives

Résumé en anglais

The obesity paradox describes the phenomenon in which obesity is associated with increased cancer risk but improved survival in patients treated with immune checkpoint inhibitors.1,2 Research suggests that biological changes due to adiposity, like alterations in tumor metabolism, immune environment, and angiogenesis, may explain this paradox.3,4 Meanwhile, adoptive cell therapy (ACT) is being developed for solid tumors despite challenges with heterogeneous tumor responses and toxic effects. The association of obesity with the efficacy and safety of ACT in patients with solid tumors is unclear. This retrospective multicohort analysis investigates this association in patients treated in various ACT clinical trials.